Ignite Creation Date:
2024-05-06 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06130254
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2023-11-08
Brief Title:
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib MRTX849 in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors With a Focus on Gynecological Breast Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Organization Data
Organization:
MD Anderson Cancer Center
Class:
OTHER
Study ID:
2022-0136
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MD Anderson Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Mirati Therapeutics Inc | INDUSTRY |